For patients experiencing lightheadedness, the genetic test ($99 add-on after month one) can clarify whether your response pattern suggests dose sensitivity or metabolic factors requiring lifestyle modification
Because Medicare Part D is currently not permitted to cover GLP-1s for weight loss, it appears that the Centers for Medicare & Medicaid Services (CMS) will create a pilot program to cover the drugs beginning as early as April 2026
Predictors of persistent pain after total knee arthroplasty: a systematic review and meta-analysis
Conversely, the American Gastroenterological Association has not found evidence to support this precaution in their latest clinical update
Simple and elegant solutions exist
In the meantime, Mounjaro at 22.5% average weight loss remains the strongest licensed option available and produces results that, until recently, would also have seemed impossible. TRIUMPH-1 Extension: Results to 104 Weeks A pre-specified blinded extension of TRIUMPH-1 followed 532 participants with a baseline BMI of 35 or higher who completed the main 80-week study